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o r i g i n a l a r t i c l e
Attributable Inpatient Costs of Recurrent
Clostridium difficile Infections
Erik R. Dubberke, MD, MSPH;1 Eric Schaefer, MS;2 Kimberly A. Reske, MPH;1
Marya Zilberberg, MD, MPH;3 Christopher S. Hollenbeak, PhD;4
Margaret A. Olsen, PhD, MPH1,5
objective. To determine the attributable inpatient costs of recurrent Clostridium difficile infections (CDIs).
design. Retrospective cohort study.
setting. Academic, urban, tertiary care hospital.
patients. A total of 3,958 patients aged 18 years or more who developed an initial CDI episode from 2003 through 2009.
methods. Data were collected electronically from hospital administrative databases and were supplemented with chart review. Patients
with an index CDI episode during the study period were followed up for 180 days from the end of their index hospitalization or the end
of their index CDI antibiotic treatment (whichever occurred later). Total hospital costs during the outcome period for patients with recurrent
versus a single episode of CDI were analyzed using zero-inflated lognormal models.
results. There were 421 persons with recurrent CDI (recurrence rate, 10.6%). Recurrent CDI case patients were significantly more
likely than persons without recurrence to have any hospital costs during the outcome period (P ! .001). The estimated attributable cost
of recurrent CDI was $11,631 (95% confidence interval, $8,937–$14,588).
conclusions. The attributable costs of recurrent CDI are considerable. Patients with recurrent CDI are significantly more likely to
have inpatient hospital costs than patients who do not develop recurrences. Better strategies to predict and prevent CDI recurrences are
needed.
Infect Control Hosp Epidemiol 2014;35(11):1400-1407
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Clostridium difficile infection (CDI) is a formidable challenge.
Although most cases of CDI are successfully treated, 10%–
30% of patients experience a CDI recurrence.1,2 There are
relatively few published studies that specifically examine re-
current CDI. A number of risk factors for recurrent CDI have
been reported, most commonly older age,1,3-10 higher severity
of illness,4,6 hospitalization after initial CDI,10,11 receipt of an-
tibiotics during the period after initial CDI,1,3,4,6,7,11,12 and re-
ceipt of antacids.1,3,7,13 In addition, Pepin et al9 and Petrella
et al14 have reported increased recurrence rates associated with
the 027/NAP1/BI strain.
Data on the economic burden of recurrent CDI on the
healthcare system are extremely sparse. McFarland et al8 have
published the only estimates of costs associated with recurrent
CDI, estimating that recurrent CDI costs $3,103 per episode
and $10,970 over a patient’s lifetime. While these estimates
are the best data currently available, they predate the emer-
gence of the 027/NAP1/BI strain and do not estimate the
attributable costs associated with recurrent CDI. The objec-
tive of this study was to determine the attributable inpatient




This study was conducted at Barnes-Jewish Hospital (BJH),
an academic tertiary care facility in St. Louis, Missouri. Data
were collected electronically from the hospital’s electronic
medical records and from the Medical Informatics and
Trendstar financial databases. The Informatics database was
queried to identify all patients with positive C. difficile toxin
assay results collected from January 1, 2003, through Decem-
ber 31, 2009. The BJH laboratory accepts only diarrheal stool
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samples for C. difficile testing. Two toxin assays were used
during the study period (TechLab C. difficile Toxin A/B II
before July 2004 and again after May 2009; Remel ProSpec
T C. difficile A/B from July 2004 through May 2009). Ad-
ditional electronic data included demographics, admission
and discharge dates, admission type (eg, inpatient, outpatient,
or emergency department), International Classification of Dis-
eases, 9th Revision, Clinical Modification (ICD-9-CM) diag-
nosis and procedure codes, inpatient medications, and lab-
oratory results. In addition, medical records were reviewed
to identify medications on hospital admission and discharge
and whether the patient received a diagnosis of recurrent CDI.
Total hospital costs (direct, indirect, and fixed) and major
diagnostic category (MDC) codes were collected from Trend-
star. Death dates were collected from the Informatics database
and the Social Security Death Index. ICD-9-CM discharge
codes from the index admission and any admissions within
the previous year were classified according to Charlson-Deyo
categories.15,16
Definitions
A CDI index hospitalization was defined as the first inpatient
hospitalization during the study period in which the patient
had a positive C. difficile toxin assay. All index CDI cases had
a positive toxin assay at BJH. The outcome period was defined
as 180 days after the end of the index hospitalization or the
end of the patient’s index CDI antibiotic treatment, whichever
occurred later. A recurrent CDI case was defined as a patient
who had documentation of recurrent CDI within 42 days of
the end of CDI antibiotic treatment, either by positive toxin
assay or by clinical diagnosis documented in the medical
record (history of a positive laboratory test as an outpatient
or at an outside healthcare facility and symptoms consistent
with CDI). We used 42 days as the risk period to develop
recurrent CDI on the basis of the current surveillance defi-
nition of 8 weeks (ie, 56 days) between episodes to be con-
sidered recurrent CDI.17 Since the recommended CDI treat-
ment duration is 10–14 days,18 the risk period for recurrent
CDI after the end of treatment using the surveillance defi-
nition is 42–46 days. Patients were included in the study only
once.
Exclusion Criteria
Patients who were less than 18 years old, had a documented
history of CDI (either by positive toxin assay or recorded in
the medical record) in the 60 days before the study period,
or were admitted for less than 0.75 days during their index
CDI admission were excluded. Patients who experienced a
CDI recurrence during the index hospitalization were also
excluded because of the difficulty in separating costs asso-
ciated with each CDI episode. Patients who died during their
index hospitalization or were discharged on hospice were
excluded. Readmissions that began during the 180-day out-
come period but ended after the 180-day outcome period
were excluded. For readmissions that began prior to the out-
come period, costs were prorated to include only those days
that occurred within the outcome period.
Statistical Analyses
The total hospital cost during the outcome period was defined
as the cumulative sum of all costs for hospital readmissions
during the 180-day outcome period. All hospital readmission
costs were inflated to 2010 dollars based on the year of dis-
charge using the medical care component of the consumer
price index.
Zero-inflated lognormal models were used to identify fac-
tors associated with total hospital readmission costs during
the outcome period because 55% of patients had no re-
admissions during the 180-day outcome period and thus no
readmission costs.19 The models had 2 components: a logistic
regression component modeling the probability of zero costs
(ie, no readmissions during the outcome period), and a log-
normal regression component modeling the mean of log costs
given nonzero costs (ie, 1 or more readmissions during the
outcome period). Cost data were normally distributed after
log transformation.
Two models were fitted. The first model included only
recurrent CDI status. The full model included recurrent CDI
status and other relevant covariates. Missing body mass index
(BMI) values (n p 31; 0.8%) were imputed at the median
of 26. All covariates were included in both components of
the model.
Odds ratios (ORs) were calculated for the logistic com-
ponent and cost ratios (CRs) were calculated for the log-
normal component for all covariates in the model, with cor-
responding 95% confidence intervals (CI). Quartiles of age
were used in the model since exploratory graphical methods
and spline fits indicated nonlinear associations, especially for
the lognormal component. All other variables were categor-
ical. The quasi-maximum-likelihood estimator was used to
back-transform log costs to actual dollar costs.20
Overall mean costs were calculated by multiplying the es-
timated probability of nonzero cost from the logistic model
times the expected cost from the lognormal portion of the
model. Differences in overall mean costs between exposures
(eg, recurrent CDI vs no recurrent CDI) were calculated using
the average predicted value (APV) method.21 The APV
method is useful to understand how overall mean costs differ
by covariates, regardless of the mechanism(s) by which the
differences may arise. The APV method was applied by cal-
culating predicted costs from the fitted model for both levels
of the variable of interest (eg, recurrent CDI vs no recurrent
CDI) separately for all patients in the data set. Then, the
mean difference was calculated across all patients. The
method was applied separately for all covariates in the model
to obtain differences in overall mean costs for all covariates.
Bootstrapping (500 samples) and the percentile method were
used to calculate 95% CIs. The difference in overall mean
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table 1. Percentages of Zero and Nonzero Costs by All Variables
Variable Zero cost, no. (%) Nonzero cost, no. (%) Total (n p 3,958)
Recurrent CDI 45 (10.7) 376 (89.3) 421
No recurrent CDI 2,111 (59.7) 1,426 (40.3) 3,637
Age quartile
!49 years 485 (50.8) 470 (49.2) 955
49 to !62 years 537 (52.1) 493 (47.9) 1,030
62 to !74 years 530 (54.6) 441 (45.4) 971
≥74 years 604 (60.3) 398 (39.7) 1,002
Sex
Female 1,069 (55.8) 846 (44.2) 1,915
Male 1,087 (53.2) 956 (46.8) 2,043
Race
White 1,529 (56.2) 1,192 (43.8) 2,721
Nonwhite 627 (50.7) 610 (49.3) 1,237
Body mass index
Missing 29 (93.5) 2 (6.5) 31
Underweight 169 (53.1) 149 (46.9) 318
Normal weight 745 (53.1) 658 (46.9) 1,403
Overweight 592 (53.2) 520 (46.8) 1,112
Obese 621 (56.8) 473 (43.2) 1,094
Charlson composite score
0 439 (65.5) 231 (34.5) 670
1 391 (61.6) 244 (38.4) 635
2 529 (53.9) 452 (46.1) 981
3 263 (51.2) 251 (48.8) 514
4 125 (45.3) 151 (54.7) 276
≥5 409 (46.4) 473 (53.6) 882
Charlson comorbidities
Myocardial infarction 161 (48.2) 173 (51.8) 334
Congestive heart failure 449 (50.8) 434 (49.2) 883
Peripheral vascular disease 156 (53.8) 134 (46.2) 290
Cerebrovascular disease 151 (54.3) 127 (45.7) 278
Chronic renal failure 83 (41.1) 119 (58.9) 202
Dementia 15 (53.6) 13 (46.4) 28
Chronic obstructive pulmonary disease 524 (54.2) 443 (45.8) 967
Rheumatologic disease 87 (55.8) 69 (44.2) 156
Peptic ulcer disease 92 (57.5) 68 (42.5) 160
Any liver disease 107 (47.6) 118 (52.4) 225
Any diabetes 521 (49.7) 527 (50.3) 1,048
Paraplegia/hemiplegia 43 (50.0) 43 (50.0) 86
Cancer (excluding leukemia/lymphoma) 404 (50.6) 395 (49.4) 799
Leukemia/lymphoma 299 (43.5) 389 (56.5) 688
Metastatic solid tumor 236 (50.3) 233 (49.7) 469
HIV/AIDS 26 (35.1) 48 (64.9) 74
MDC
0 (unassigned principal diagnosis) 404 (60.4) 265 (39.6) 669
1 (diseases of the nervous system) 90 (60.8) 58 (39.2) 148
4 (diseases of the respiratory system) 160 (52.3) 146 (47.7) 306
5 (diseases of the circulatory system) 188 (51.6) 176 (48.4) 364
6 (diseases of the digestive system) 615 (58.8) 431 (41.2) 1,046
7 (diseases of the hepatobiliary system and pancreas) 109 (56.5) 84 (43.5) 193
8 (diseases of the musculoskeletal system and connective tissue) 72 (55.4) 58 (44.6) 130
10 (endocrine, nutritional, and metabolic diseases) 43 (46.2) 50 (53.8) 93
11 (diseases of the kidney and urinary tract) 140 (49.6) 142 (50.4) 282
13 (diseases of the female reproductive system) 28 (70.0) 12 (30.0) 40
16 (diseases of blood, blood-forming organs, immunologic) 24 (36.9) 41 (63.1) 65
17 (myeloproliferative diseases) 79 (33.8) 155 (66.2) 234
18 (infectious and parasitic diseases) 108 (49.3) 111 (50.7) 219
21 (injuries, poisonings, toxic effects of drugs) 18 (56.3) 14 (43.8) 32
25 (HIV infections) 16 (42.1) 22 (57.9) 38
All others 62 (62.6) 37 (37.4) 99
note. Row percentages are used. CDI, Clostridium difficile infection; HIV, human immunodeficiency virus; MDC, major diagnostic
category.
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table 2. Estimated Probabilities and Overall Mean Costs











No 0.597 20,964 8,448
Yes 0.107 21,942 19,594
a Overall mean costs p (1  probability of zero cost) # ex-
pected mean cost given nonzero cost.
cost between patients with recurrent CDI and patients with-
out recurrent CDI was used as the measure for attributable
cost.
The data set included patients who died during the 180-
day outcome period. A sensitivity analysis was performed to
determine the effect of death on the final cost estimates for
recurrent CDI. The zero-inflated lognormal models were refit
to the data set excluding patients who died during the out-
come period. The APV with bootstrapping was used to es-
timate attributable costs of recurrent CDI.
This study was approved by the Washington University
School of Medicine Human Research Protection Office. Sta-
tistical analyses were performed with SAS version 9.3 and R
version 3.0.1.
results
A total of 4,615 patients were evaluated for the study; 3,958
patients met the inclusion criteria and were included. The
CDI recurrence rate was 10.6% (n p 421). Of the 421 patients
with recurrent CDI, 302 (72%) had a positive toxin assay at
BJH. The study population consisted of 2 distinct subpop-
ulations: patients with zero costs (ie, no readmissions) during
the outcome period (n p 2,156; 55%), and patients with
nonzero costs (ie, 1 or more readmissions) during the out-
come period (n p 1,802; 45%; Table 1). Total hospital costs
for the subpopulation with nonzero costs were highly skewed,
with a median of $10,560 and a distribution that ranged from
$213 to $1,014,000 (interquartile range, $4,333–$23,980);
89% of recurrent CDI cases had nonzero costs (n p 376),
compared with 40% of patients without recurrent CDI (n p
1,426; P ! .001).
For the base regression model, which included only re-
current CDI status, the logistic portion of the model indicated
that the odds of zero costs (ie, no readmissions) for patients
with recurrent CDI were 0.08 (95% CI, 0.06–0.11; P ! .001)
compared with patients without recurrent CDI. The model
also indicated that, given nonzero total cost (ie, 1 or more
readmissions), patients with recurrent CDI had an average
of 5% larger total costs (CR, 1.05) than patients without
recurrent CDI (95% CI, 0.91–1.20; P p 0.52). Stated con-
versely, patients with recurrent CDI were 12.5 times more
likely to accrue any readmission costs (ie, be readmitted) than
were patients without recurrent CDI. However, patients with
recurrent CDI who were readmitted had only 5% larger costs
than patients without recurrent CDI who were readmitted.
The expected probabilities of zero and nonzero costs and
the overall mean costs of recurrent CDI status are shown in
Table 2. Patients without recurrent CDI had a 0.597 probability
of zero costs, compared with a 0.107 probability for recurrent
CDI patients. For patients with recurrent CDI who had nonzero
costs, the expected mean cost was $21,942, and the expected
overall mean cost for recurrent CDI was $19,594; this value
includes both the probability of zero costs and the expected
mean cost given nonzero costs. The difference in overall mean
costs between groups was $11,146 ($19,594  $8,448).
For the regression model that included recurrent CDI
status and adjustments for other demographic variables (“full
model”), recurrent CDI was significantly associated with
lower odds of zero costs (OR, 0.07 [95% CI, 0.05–0.10];
P ! .001) compared with patients without recurrent CDI
(Table 3). Nonwhite race, various MDC codes, and several
comorbidities were also associated with significantly lower
odds of zero cost. Increasing age was associated with higher
odds of zero cost.
For the subpopulation with nonzero costs, recurrent CDI
status was marginally associated (P p .07) with increased
costs (CR, 1.13 [95% CI, 0.99–1.30]). MDC codes 17 (mye-
loproliferative disease), 0 (not classified), 7 (hepatobiliary and
pancreas disease), and 18 (infectious and parasitic diseases)
were associated with increased costs relative to MDC code 6
(diseases of the digestive system; this was chosen as the ref-
erence category because it was the most commonly identified
MDC category in the data). Myocardial infarction, rheu-
matologic disease, and leukemia/lymphoma were also asso-
ciated with increased costs. Older age (more than or equal
to 74 years) and cerebrovascular disease were associated with
decreased costs.
Differences in overall mean costs as estimated by the APV
method are shown in Figure 1. After adjusting for all other
variables in the model, older age was associated with lower
overall mean costs, while recurrent CDI was associated with
higher overall mean costs. After adjusting for age, sex, race,
BMI, MDC code, and comorbidities, the attributable cost of
recurrent CDI was $11,631 (95% CI, $8,937–$14,588).
Sensitivity analysis. Twenty-seven percent of the study
population (n p 1,065) died during the 180-day outcome
period. Patients who died were more likely to have nonzero
costs (52% vs 43%) and higher median costs ($14,618 vs
$9,255) than patients who survived for the full 180 days.
Patients with recurrent CDI were more likely to die during
the outcome period (36.6% vs 25.8%) than patients without
recurrent CDI. After adjusting for all demographic variables
in the data set that excluded individuals who died and after
applying the APV method, the attributable cost of recurrent
CDI was $8,709 (95% CI, $6,219–$11,529).
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table 3. Estimated Odds Ratios (ORs) and Cost Ratios (CRs) with 95% Confidence Intervals (CIs) from the Model That
Adjusted for All Variables
Variable
OR (95% CI) for
zero cost P
CR (95% CI) given
nonzero cost P
Recurrent CDI (vs none) 0.07 (0.05–0.10) !.001 1.13 (0.99–1.30) .07
Age quartile
!49 years 1.00 (reference) 1.00 (reference)
49 to !62 years 1.22 (1.01–1.49) .04 0.90 (0.77–1.05) .18
62 to !74 years 1.44 (1.17–1.76) !.001 0.92 (0.78–1.08) .32
≥74 years 1.86 (1.50–2.30) !.001 0.79 (0.67–0.94) .009
Male (vs female) 0.98 (0.85–1.13) .83 0.95 (0.85–1.07) .41
Nonwhite (vs white) 0.79 (0.68–0.92) .003 1.02 (0.90–1.16) .74
Body mass index
Normal weight 1.00 (reference) 1.00 (reference)
Underweight 1.08 (0.82–1.41) .59 0.99 (0.80–1.22) .94
Overweight 1.07 (0.90–1.27) .46 0.96 (0.84–1.10) .60
Obese 1.22 (1.02–1.46) .03 1.01 (0.88–1.17) .87
MDC
6 (diseases of the digestive system) 1.00 (reference) 1.00 (reference)
0 (unassigned principal diagnosis) 1.09 (0.86–1.37) .47 1.49 (1.23–1.81) !.001
1 (diseases of the nervous system) 0.99 (0.66–1.47) .95 1.55 (1.11–2.18) .01
4 (diseases of the respiratory system) 0.79 (0.59–1.04) .10 1.26 (1.00–1.58) .05
5 (diseases of the circulatory system) 0.74 (0.56–0.97) .03 1.12 (0.90–1.40) .30
7 (diseases of the hepatobiliary system and pancreas) 1.06 (0.75–1.50) .73 1.48 (1.12–1.97) .006
8 (diseases of the musculoskeletal system and connective tissue) 0.70 (0.47–1.03) .07 1.14 (0.82–1.58) .43
10 (endocrine, nutritional, and metabolic diseases) 0.65 (0.41–1.04) .07 1.21 (0.86–1.71) .28
11 (diseases of the kidney and urinary tract) 0.67 (0.50–0.89) .006 1.16 (0.93–1.45) .20
13 (diseases of the female reproductive system) 1.82 (0.86–3.86) .12 1.24 (0.63–2.43) .54
16 (diseases of blood, blood-forming organs, immunologic) 0.49 (0.28–0.85) .01 1.18 (0.80–1.73) .40
17 (myeloproliferative diseases) 0.45 (0.32–0.65) !.001 2.25 (1.74–2.91) !.001
18 (infectious and parasitic diseases) 0.68 (0.49–0.93) .02 1.30 (1.02–1.67) .04
21 (injuries, poisonings, toxic effects of drugs) 0.72 (0.34–1.52) .39 1.29 (0.69–2.41) .42
25 (HIV infections) 1.55 (0.55–4.36) .40 1.15 (0.58–2.25) .69
All others 1.18 (0.74–1.87) .48 0.98 (0.66–1.45) .92
Charlson comorbidities
Myocardial infarction 0.71 (0.54–0.92) .009 1.23 (1.01–1.51) .04
Congestive heart failure 0.75 (0.63–0.90) .002 1.13 (0.98–1.30) .10
Peripheral vascular disease 0.99 (0.75–1.30) .95 1.22 (0.98–1.52) .07
Cerebrovascular disease 1.08 (0.80–1.46) .63 0.77 (0.61–0.98) .03
Chronic renal failure 0.60 (0.44–0.83) .002 1.02 (0.81–1.29) .85
Dementia 0.97 (0.40–2.33) .94 1.39 (0.71–2.71) .34
Chronic obstructive pulmonary disease 0.97 (0.82–1.15) .75 1.00 (0.88–1.15) .96
Rheumatologic disease 1.06 (0.74–1.52) .74 1.45 (1.09–1.94) .01
Peptic ulcer disease 1.22 (0.85–1.75) .27 1.04 (0.78–1.40) .77
Any liver disease 0.60 (0.44–0.81) !.001 1.15 (0.91–1.45) .25
Any diabetes 0.81 (0.69–0.95) .01 1.08 (0.95–1.23) .23
Paraplegia/hemiplegia 0.78 (0.48–1.26) .31 0.96 (0.67–1.38) .84
Cancer (excluding leukemia/lymphoma) 0.63 (0.50–0.79) !.001 0.96 (0.80–1.14) .62
Leukemia/lymphoma 0.53 (0.42–0.67) !.001 1.37 (1.15–1.63) !.001
Metastatic solid tumor 0.94 (0.71–1.23) .65 0.98 (0.80–1.22) .88
HIV/AIDS 0.40 (0.18–0.87) .02 1.17 (0.74–1.87) .50
note. CDI, Clostridium difficile infection; HIV, human immunodeficiency virus; MDC, major diagnostic category.
discussion
This study is the first to estimate the attributable inpatient
costs of recurrent CDI. Previous estimates by Dubberke et
al22 and Kyne et al23 of the attributable costs of any CDI per
hospitalization were between $2,400 and $3,700, but neither
of these studies included recurrent CDI. Dubberke et al22
estimated the attributable cost of CDI over the 180 days after
initial infection as $5,042–$7,179, and while this estimate
surely includes some of the costs associated with recurrence,
the analysis was not limited specifically to recurrent CDI
cases. As mentioned previously, only McFarland et al8 have
studied the costs associated with recurrent CDI; their esti-
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figure 1. Forest plots of overall mean differences in total costs (filled circles) with 95% confidence intervals (line segments) for each
covariate relative to the reference group. BMI, body mass index; CDI, Clostridium difficile infection; CHF, congestive heart failure; COPD,
chronic obstructive pulmonary disease; CRF, chronic renal failure; CVD, cerebrovascular disease; HIV, human immunodeficiency virus;
Leuk/lymph, leukemia/lymphoma; MDC, major diagnostic category; Mets, metastatic solid tumor; MI, myocardial infarction; PUD, peptic
ulcer disease; PVD, peripheral vascular disease; Rheum, rheumatologic disease.
mates were $3,103 per recurrent CDI episode and $10,970
over a patient’s lifetime ($4,152 per episode and $14,675 life-
time in 2010 dollars, assuming that McFarland et al’s esti-
mates used 1998 dollars), but they did not determine attrib-
utable costs.
The estimated attributable inpatient costs of recurrent CDI
over the 180 days after the initial episode of CDI reported
in this study was $11,631 (95% CI, $8,937–$14,588). This
value reflects that patients with recurrent CDI would be ex-
pected to accrue about $11,000 more per patient, on average,
than those without recurrent CDI. This estimate is signifi-
cantly larger than McFarland et al’s per-episode estimate of
$3,103 ($4,152 in 2010 dollars) and is comparable to their
lifetime estimate of $10,970 ($14,675 in 2010 dollars). These
estimates suggest that the attributable cost of recurrent CDI
has increased since publication of McFarland et al’s study in
1999. They were able to capture some outpatient costs (clinic
visits), whereas outpatient costs were not included in our
study. McFarland et al’s definition of “lifetime” costs was from
a patient’s first episode of CDI through enrollment into a
clinical trial of combination treatment for recurrent CDI (and
the next recurrence after enrollment); many patients were
followed up for more than 180 days. If outpatient costs had
been included in our current study and patients had been
followed up for a longer period of time, the attributable cost
of CDI would likely have been even larger.
The primary mechanism of the increased costs associated
with CDI recurrence was the increased probability of having
any costs (ie, being readmitted) during the outcome period
for patients with recurrent CDI. While the recurrent CDI
attributable cost estimate among patients with any costs (both
recurrent CDI and nonrecurrent CDI patients with nonzero
costs) during the outcome period was of borderline statistical
significance (P p .07), recurrent CDI patients were 12.5 times
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more likely to have any hospital costs than nonrecurrent CDI
patients. Recurrent CDI may have been the primary reason
for readmission, or recurrence may have occurred during a
readmission and prolonged or complicated the hospitaliza-
tion. In either situation, recurrent CDI is a potentially mod-
ifiable factor that significantly increases inpatient costs.
Although recurrent CDI was associated with only marginally
increased hospital costs among all readmitted patients, since
recurrent CDI patients were much more likely to be readmitted
to the hospital, this translated to an attributable cost estimate
of $11,631 (95% CI, $8,937–$14,588) per patient. There were
421 recurrent CDI cases, so the total estimated attributable cost
of recurrent CDI would be $4,896,651 (95% CI, $3,762,477–
$6,141,548; 2010 dollars) for our single facility over the 7 years
examined in our study. These costs reflect only facility costs
and do not include provider charges. Furthermore, this esti-
mate does not take into account other quality-of-life issues for
patients, such as loss of work, prescription drug costs, or in-
creased morbidity due to recurrence.
The relationship among death, recurrent CDI, and cost
estimates is somewhat unclear. Patients who died during the
outcome period were necessarily followed up for less than
180 days, suggesting that the total costs were biased down-
ward compared with those for patients followed up for the
full period. On the other hand, deaths are typically associated
with large hospital costs.24,25 In our analyses, patients with
recurrent CDI were more likely to die, and patients who died
were more likely to have nonzero costs. These two findings
indicated that the extra deaths during the outcome period
for patients with recurrent CDI may have resulted in an in-
crease in costs attributable to recurrent CDI. Indeed, the at-
tributable cost of recurrent CDI was only $8,709 when ex-
cluding patient deaths during the outcome period.
There are several limitations to this study. Most of the data
used in this study were administrative and collected elec-
tronically from hospital databases. Medical records were re-
viewed to confirm several of the most important variables in
this study (e.g., recurrent CDI status and postdischarge an-
tibiotic use). Data on C. difficile strain type were not available,
so it was not possible to differentiate between CDI relapse
and reinfection.
The primary limitation of this study is the use of hospital
laboratory results to detect recurrent CDI cases. While we
identified all positive C. difficile toxin results from our hos-
pital’s laboratory and reviewed charts to identify additional
CDI recurrences, we likely did not capture recurrent cases
that were identified and treated exclusively at other hospitals
or at outpatient clinics. These constitute 2 separate patient
groups. Bias due to exclusion of cases diagnosed at other
inpatient facilities should have been lessened since medical
records were reviewed to identify recurrent CDI cases diag-
nosed at other facilities and transferred to the study hospital
for treatment. Exclusion of recurrent CDI patients treated at
other inpatient facilities would likely lead to lower estimates
of attributable costs because those patients’ readmission costs
were not included in analyses. In contrast, exclusion of pa-
tients diagnosed and treated solely as outpatients may have
biased the population toward more severely ill recurrent CDI
patients who required hospitalization. In this case, the true
odds of zero costs may be lower than reported here. However,
the exclusion of outpatient recurrent CDI cases would not
impact the CRs given nonzero costs.
Recurrent CDI is known to be an important cause of con-
tinued morbidity after initial CDI. The results of this study,
which suggests that the attributable costs of a single recurrent
CDI case over 6 months are in excess of $11,000, should add
further impetus to the need for better prevention of and
treatment for recurrent CDI cases. This study also highlights
the need for additional research on recurrent CDI, specifically
with respect to the relationship between recurrent CDI and
mortality, the economic costs of recurrent CDI outside in-
patient facilities, and the effect of recurrent CDI on quality
of life. Better methods of identifying patients at risk for re-
current CDI and preventing those recurrences would decrease
the economic burden of recurrent CDI.
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